Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab
To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1 antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated with nivolumab for platinum-refractory recurrent or metastatic HNSCC were retrospectively reviewed. Fifty-three patients treated...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2018-11-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/10/12/466 |
| _version_ | 1797763137537048576 |
|---|---|
| author | Daisuke Nishikawa Hidenori Suzuki Yusuke Koide Shintaro Beppu Shigenori Kadowaki Michihiko Sone Nobuhiro Hanai |
| author_facet | Daisuke Nishikawa Hidenori Suzuki Yusuke Koide Shintaro Beppu Shigenori Kadowaki Michihiko Sone Nobuhiro Hanai |
| author_sort | Daisuke Nishikawa |
| collection | DOAJ |
| description | To investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1 antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated with nivolumab for platinum-refractory recurrent or metastatic HNSCC were retrospectively reviewed. Fifty-three patients treated between April 2017 and March 2018 were included in the study. The median progression-free survival (PFS) and overall survival (OS) were 2.5 and 8.7 months, respectively. In the univariate analysis, performance status (PS) ≥ 3, relative neutrophil count ≥ 0.65, relative lymphocyte count ≥ 0.17, and relative eosinophil count (REC) ≥ 0.015 were significantly associated with both PFS and OS. On multivariate analysis, PS ≥ 3 and REC ≥ 0.015 were significantly associated with PFS and OS. Low REC and poor PS were independent poor prognostic factors for both PFS and OS in patients with recurrent or metastatic HNSCC treated with nivolumab. |
| first_indexed | 2024-03-12T19:37:22Z |
| format | Article |
| id | doaj.art-4ae63f38fa904926a47b40716a1ef04d |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-12T19:37:22Z |
| publishDate | 2018-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-4ae63f38fa904926a47b40716a1ef04d2023-08-02T04:05:09ZengMDPI AGCancers2072-66942018-11-01101246610.3390/cancers10120466cancers10120466Prognostic Markers in Head and Neck Cancer Patients Treated with NivolumabDaisuke Nishikawa0Hidenori Suzuki1Yusuke Koide2Shintaro Beppu3Shigenori Kadowaki4Michihiko Sone5Nobuhiro Hanai6Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanDepartment of Otorhinolaryngology, Nagoya University Graduate School of Medicine, Nagoya 466-8560, JapanDepartment of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya 464-8681, JapanTo investigate whether peripheral blood biomarkers predict the outcome of anti-PD-1 antibody treatment for head and neck squamous cell carcinoma (HNSCC). Patients treated with nivolumab for platinum-refractory recurrent or metastatic HNSCC were retrospectively reviewed. Fifty-three patients treated between April 2017 and March 2018 were included in the study. The median progression-free survival (PFS) and overall survival (OS) were 2.5 and 8.7 months, respectively. In the univariate analysis, performance status (PS) ≥ 3, relative neutrophil count ≥ 0.65, relative lymphocyte count ≥ 0.17, and relative eosinophil count (REC) ≥ 0.015 were significantly associated with both PFS and OS. On multivariate analysis, PS ≥ 3 and REC ≥ 0.015 were significantly associated with PFS and OS. Low REC and poor PS were independent poor prognostic factors for both PFS and OS in patients with recurrent or metastatic HNSCC treated with nivolumab.https://www.mdpi.com/2072-6694/10/12/466nivolumabhead and necksquamous cell carcinomaprognostic factor |
| spellingShingle | Daisuke Nishikawa Hidenori Suzuki Yusuke Koide Shintaro Beppu Shigenori Kadowaki Michihiko Sone Nobuhiro Hanai Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab Cancers nivolumab head and neck squamous cell carcinoma prognostic factor |
| title | Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab |
| title_full | Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab |
| title_fullStr | Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab |
| title_full_unstemmed | Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab |
| title_short | Prognostic Markers in Head and Neck Cancer Patients Treated with Nivolumab |
| title_sort | prognostic markers in head and neck cancer patients treated with nivolumab |
| topic | nivolumab head and neck squamous cell carcinoma prognostic factor |
| url | https://www.mdpi.com/2072-6694/10/12/466 |
| work_keys_str_mv | AT daisukenishikawa prognosticmarkersinheadandneckcancerpatientstreatedwithnivolumab AT hidenorisuzuki prognosticmarkersinheadandneckcancerpatientstreatedwithnivolumab AT yusukekoide prognosticmarkersinheadandneckcancerpatientstreatedwithnivolumab AT shintarobeppu prognosticmarkersinheadandneckcancerpatientstreatedwithnivolumab AT shigenorikadowaki prognosticmarkersinheadandneckcancerpatientstreatedwithnivolumab AT michihikosone prognosticmarkersinheadandneckcancerpatientstreatedwithnivolumab AT nobuhirohanai prognosticmarkersinheadandneckcancerpatientstreatedwithnivolumab |